SHUBHAM PANT to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications SHUBHAM PANT has written about Antineoplastic Agents, Immunological.
Connection Strength
0.372
-
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase?II Trial. Adv Ther. 2021 08; 38(8):4581-4591.
Score: 0.101
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.092
-
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019 11; 20(11):1544-1555.
Score: 0.089
-
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 09 18; 7(1):253.
Score: 0.089